Symyx Technologies acquires Integrity Biosolution

Symyx Technologies has acquired Integrity Biosolution, of Camarillo, California, in an all-cash transaction. Specific terms of the purchase were not disclosed.

IntegrityBio is a leader in contract formulation research and analytical services, providing high quality, cost-effective formulation and stability solutions for large molecule biopharmaceuticals along with GMP fill/finish services for Phase I and II clinical trial volumes. The acquisition expands Symyx's research service offerings in life sciences into biologic formulations, complementing its existing chemical formulations services.

"The acquisition of IntegrityBio enables Symyx to offer customers a highly competitive formulation service in biologics," said Isy Goldwasser, ceo of Symyx. "We can leverage our expertise in informatics and automated parallel experimentation to improve the consistency, accuracy, data capture capabilities and quality of reporting within this market. This is an important change in formulation outsourcing."

Dr Byeong Chang, IntegrityBio's founder, will continue to oversee technical and operational functions as chief scientific officer.

Earlier this year Symyx launched new pre-formulation, formulation and process development research services for early stage pharmaceutical development. In July the company entered into a one-year agreement with Bristol-Myers Squibb to perform solubility research services and help it achieve a greater level of r&d efficiency.